Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany

  • Evotec SE announced today that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-clinical-and-commercial-drug-substance-manufacturing-with-acquisition-of-central-glass-germany-6207

    Du magst vielleicht auch